Natera, Inc. (NASDAQ:NTRA) Receives Average Recommendation of “Buy” from Analysts

Shares of Natera, Inc. (NASDAQ:NTRA) have received an average rating of “Buy” from the sixteen brokerages that are covering the company, Marketbeat Ratings reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $178.12.

NTRA has been the subject of several analyst reports. Guggenheim upped their target price on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 17th. Robert W. Baird upped their target price on Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. JPMorgan Chase & Co. boosted their price target on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Canaccord Genuity Group reissued a “buy” rating and set a $180.00 price target on shares of Natera in a research report on Wednesday, February 26th. Finally, Piper Sandler upped their target price on Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th.

Insider Buying and Selling at Natera

In other Natera news, CFO Michael Burkes Brophy sold 25,931 shares of the stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07. Following the completion of the transaction, the chief financial officer now directly owns 109,665 shares of the company’s stock, valued at approximately $18,091,435.05. This trade represents a 19.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John Fesko sold 663 shares of the stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the transaction, the insider now directly owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. The trade was a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 298,946 shares of company stock worth $47,803,462 over the last quarter. 7.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Natera

Several large investors have recently modified their holdings of NTRA. LRI Investments LLC purchased a new stake in shares of Natera during the fourth quarter worth $29,000. Blue Trust Inc. raised its holdings in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after buying an additional 97 shares in the last quarter. Versant Capital Management Inc increased its stake in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares during the period. Covestor Ltd increased its stake in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the period. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after purchasing an additional 261 shares during the period. 99.90% of the stock is owned by institutional investors.

Natera Stock Down 2.0 %

NTRA opened at $146.28 on Friday. Natera has a one year low of $83.13 and a one year high of $183.00. The company has a market cap of $19.78 billion, a price-to-earnings ratio of -83.11 and a beta of 1.80. The business’s fifty day moving average is $162.76 and its two-hundred day moving average is $149.26. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Analysts anticipate that Natera will post -1.49 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.